The 65 rating InvestorsObserver gives to Keros Therapeutics Inc (KROS) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 77 percent of stocks in the Biotechnology industry, KROS’s 65 overall rating means the stock scores better than 65 percent of all stocks.
KROS has an Overall Score of 65. Find out what this means to you and get the rest of the rankings on KROS!
Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. InvestorsObserver makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.
What's Happening With Keros Therapeutics Inc Stock Today?
Keros Therapeutics Inc (KROS) stock is down -3.18% while the S&P 500 is up 0.29% as of 9:56 AM on Wednesday, Mar 27. KROS is lower by -$2.10 from the previous closing price of $66.11 on volume of 65,135 shares. Over the past year the S&P 500 has risen 31.41% while KROS is up 54.02%. KROS lost -$5.20 per share the over the last 12 months.
Click Here to get the full Stock Report for Keros Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
